Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$27.8 - $45.35 $183,202 - $298,856
6,590 New
6,590 $287,000
Q1 2023

May 15, 2023

BUY
$36.54 - $54.26 $267,217 - $396,803
7,313 New
7,313 $271,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Teza Capital Management LLC Portfolio

Follow Teza Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Teza Capital Management LLC with notifications on news.